{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:38:23Z","timestamp":1789799903271,"version":"4.0.1"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Central High-Level Traditional Chinese Medicine Hospital Clinical Research Funding","award":["DZMG-LJRC0009"],"award-info":[{"award-number":["DZMG-LJRC0009"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Mens Health"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>The aim of this study is to systematically evaluate the association between metabolic syndrome (MetS) and key clinical parameters of benign prostatic hyperplasia (BPH), including International Prostate Symptom Score (IPSS), prostate volume (PV), and the prevalence of MetS among men with BPH. A systematic search of PubMed, Embase, Web of Science, Scopus, and the Cochrane Library was conducted from inception to March 31, 2025, with the search implementation completed on April 5, 2025 for all databases. Observational studies comparing BPH patients with and without MetS were included. Random-effects models were used to pool standardized mean differences (SMDs), mean differences (MDs), and prevalence estimates. Heterogeneity, publication bias, subgroup analyses, sensitivity analyses, and meta-regression were performed according to prespecified criteria. Ten studies involving 3,947 BPH patients met the inclusion criteria. Pooled analyses demonstrated that MetS was associated with larger prostate volume (PV) and a tendency toward higher IPSS, although the latter showed substantial variability across studies. The prevalence of MetS among BPH patients was high, with considerable geographic and temporal variation. Subgroup analyses indicated that sample size influenced effect estimates, and meta-regression identified age, sample size, and publication year as contributors to heterogeneity. MetS is closely associated with prostate enlargement and symptom burden in men with BPH. These findings highlight the metabolic\u2013urological interplay and support the integration of metabolic assessment into BPH management strategies. Large-scale prospective studies are needed to clarify causality and evaluate whether metabolic interventions can alter BPH progression.<\/jats:p>","DOI":"10.1177\/15579883261436335","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:18:21Z","timestamp":1775197101000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The Association Between Metabolic Syndrome and Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"20","author":[{"given":"Wenfeng","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbo","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephropathy, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5179-7023","authenticated-orcid":false,"given":"Yaosheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Bertocchi I. Foglietta F. Collotta D. Eva C. Brancaleone V. Thiemermann C. Collino M. (2020). The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. British Journal of Pharmacology 177(21) 4921\u20134930. https:\/\/doi.org\/10.1111\/bph.15229","DOI":"10.1111\/bph.15229"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.18565\/urology.2018.4.179-185"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.18565\/urology.2020.2.101-106"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Cai T. Ceccato T. Botti S. Kranz J. Verze P. Bonkat G. .\u2004.\u2004. Bjerklund Johansen T. E. (2025). Impact of lifestyle and the microbiome on male lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology Focus 11(4) 557\u2013559. https:\/\/doi.org\/10.1016\/j.euf.2025.04.013","DOI":"10.1016\/j.euf.2025.04.013"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Calmasini F. B. McCarthy C. G. Wenceslau C. F. Priviero F. B. M. Antunes E. Webb R. C. (2020). Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice. Pharmacological Reports 72(1) 179\u2013187. https:\/\/doi.org\/10.1007\/s43440-019-00010-3","DOI":"10.1007\/s43440-019-00010-3"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Chiarot A. Minhas M. de Maat N. M. Doan J. Nilsson M. I. Hettinga B. P. .\u2004.\u2004.Tarnopolsky M. A. (2025). A multi-ingredient supplement improves body re-composition ovarian aging markers and reproductive success in young and middle-aged female mice. Biomolecules 15(9) 1258. https:\/\/doi.org\/10.3390\/biom15091258","DOI":"10.3390\/biom15091258"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Colado-Vel\u00e1zquez J. I. Mailloux-Salinas P. Arias-Ch\u00e1vez D. J. Ledesma-Aparicio J. G\u00f3mez-Viquez N. L. Cano-Europa E. .\u2004.\u2004.Bravo G. (2023). Lipidic extract of whole tomato reduces hyperplasia oxidative stress and inflammation on testosterone-induced BPH in obese rats. International Urology and Nephrology 55(3) 529\u2013539. https:\/\/doi.org\/10.1007\/s11255-022-03383-2","DOI":"10.1007\/s11255-022-03383-2"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Daher M. Saqer T. Jabr M. Al-Mousa S. (2023). Benign prostatic hyperplasia and metabolic syndrome; prevalence and association: A cross-sectional study in Syria. BMC Urology 23(1) Article 187. https:\/\/doi.org\/10.1186\/s12894-023-01365-9","DOI":"10.1186\/s12894-023-01365-9"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Feng S. Jin Y. Ni X. Zheng H. Wu L. Xia Y. .\u2004.\u2004.Li X. (2025). FGF1(\u0394HBS) ameliorates DSS-induced ulcerative colitis by reducing neutrophil recruitment through the MAPK pathway. British Journal of Pharmacology 182(20) 5057\u20135070. https:\/\/doi.org\/10.1111\/bph.70049","DOI":"10.1111\/bph.70049"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Gacci M. Sebastianelli A. Salvi M. De Nunzio C. Vignozzi L. Corona G. .\u2004.\u2004.Serni S. (2017). Benign prostatic enlargement can be influenced by metabolic profile: Results of a multicenter prospective study. BMC Urology 17(1) Article 22. https:\/\/doi.org\/10.1186\/s12894-017-0211-9","DOI":"10.1186\/s12894-017-0211-9"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Gacci M. Vignozzi L. Sebastianelli A. Salvi M. Giannessi C. De Nunzio C. .\u2004.\u2004.Maggi M. (2013). Metabolic syndrome and lower urinary tract symptoms: The role of inflammation. Prostate Cancer and Prostatic Diseases 16(1) 101\u2013106. https:\/\/doi.org\/10.1038\/pcan.2012.44","DOI":"10.1038\/pcan.2012.44"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Gong Y. M. Wang X. Liu S. Hu X. C. Xu Y. Huang T. (2022). Simvastatin inhibits prostatic hyperplasia in rats with metabolic syndrome. International Urology and Nephrology 54(9) 2125\u20132131. https:\/\/doi.org\/10.1007\/s11255-022-03227-z","DOI":"10.1007\/s11255-022-03227-z"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Hammarsten J. H\u00f6gstedt B. Holthuis N. Mellstr\u00f6m D. (1998). Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases 1(3) 157\u2013162. https:\/\/doi.org\/10.1038\/sj.pcan.4500221","DOI":"10.1038\/sj.pcan.4500221"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"He J. Pan X. Liu D. Li J. Li Y. Wang Y. .\u2004.\u2004.Wang L. (2025). Association between metabolic syndrome and risk of benign prostatic hyperplasia: A prospective cohort study of 163\u2009975 participants. Journal of Global Health 15 04275. https:\/\/doi.org\/10.7189\/jogh.15.04275","DOI":"10.7189\/jogh.15.04275"},{"key":"e_1_3_2_16_1","unstructured":"Jan D. M. A. Khan M. Ur Rahman S. Z. Ahmad K. Yousuf M. H. (2024). Prevalence and association of benign prostatic hyperplasia and metabolic syndrome: Findings from a cross-sectional study. Journal of Population Therapeutics and Clinical Pharmacology 31(3) 1087\u20131096. https:\/\/doi.org\/10.53555\/jptcp.v31i3.5084"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"O\u2019Mahony C. J. Arshad M. A. Norton S. M. (2025). Testosterone and lower urinary tract symptoms: A narrative review. Current Urology Reports 26(1) 75. https:\/\/doi.org\/10.1007\/s11934-025-01307-y","DOI":"10.1007\/s11934-025-01307-y"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Ozden C. Ozdal O. L. Urgancioglu G. Koyuncu H. Gokkaya S. Memis A. (2007). The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European Urology 51(1) 199\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2006.05.040","DOI":"10.1016\/j.eururo.2006.05.040"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Pan J. G. Jiang C. Luo R. Zhou X. (2014). Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades. Urologia Internationalis 93(1) 10\u201316. https:\/\/doi.org\/10.1159\/000354026","DOI":"10.1159\/000354026"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.934475","article-title":"Review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines","volume":"27","author":"Parums D. V.","year":"2021","unstructured":"Parums D. V. (2021). Review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 27, e934475\u2013934471.","journal-title":"Medical Science Monitor: International Medical Journal of Experimental and Clinical Research"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Ren J. Li Y. Zhang X. Xiong M. Zhang H. An L. .\u2004.\u2004.Tian Y. (2024). Correlation between metabolic syndrome and periurethral prostatic fibrosis: Results of a prospective study. BMC Urology 24(1) Article 38. https:\/\/doi.org\/10.1186\/s12894-024-01413-y","DOI":"10.1186\/s12894-024-01413-y"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Russo G. I. Regis F. Spatafora P. Frizzi J. Urz\u00ec D. Cimino S. .\u2004.\u2004.Morgia G. (2018). Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms (MIPS Study). BJU International 121(5) 799\u2013804. https:\/\/doi.org\/10.1111\/bju.14007","DOI":"10.1111\/bju.14007"},{"key":"e_1_3_2_23_1","unstructured":"Sachdeva R. Kaur N. Kapoor P. Singla P. Thakur N. Singhmar S. (2022). Computational analysis of protein-protein interaction network of differentially expressed genes in benign prostatic hyperplasia. Molecular Cell Biology Research Communications 11(2) 85\u201396. https:\/\/doi.org\/10.22099\/mbrc.2022.43721.1746"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Sharkey C. Gu B. Long X. Tang Y. Patsatzis N. Li S. .\u2004.\u2004.Wang Z. (2025). Stromal steroid 5 alpha-reductase 2 promotes prostate growth through WNT5A-lymphoid enhancer-binding factor 1-insulin-like growth factor 1 signaling in benign prostatic hyperplasia. American Journal of Pathology 195(12) 2411\u20132430. https:\/\/doi.org\/10.1016\/j.ajpath.2025.08.011","DOI":"10.1016\/j.ajpath.2025.08.011"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"Urgesa H. E. Tereffe Z. A. Leta T. A. Nasi B. A. Hurisa S. G. (2025). Metabolic syndrome and associated factors among benign prostatic hyperplasia patients at Jimma University Medical center Jimma Southwest Ethiopia. Cardiovascular Diabetology\u2014Endocrinology Reports 11(1) 25. https:\/\/doi.org\/10.1186\/s40842-025-00226-8","DOI":"10.1186\/s40842-025-00226-8"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Wang Y. Li X. Yang H. Yin C. Wu Y. Chen X. (2025). Predictive factors of incidental prostate cancer in patients undergoing surgery for presumed benign prostatic hyperplasia: An updated systematic review and meta-analysis. Frontiers in Oncology 15 Article 1561675. https:\/\/doi.org\/10.3389\/fonc.2025.1561675","DOI":"10.3389\/fonc.2025.1561675"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Wu S. Yin X. Yang P. Gong B. Wang Z. (2025). Beneficial effects of Akkermansia muciniphila on benign prostatic hyperplasia and metabolic syndrome. Archives of Biochemistry and Biophysics 768 110294. https:\/\/doi.org\/10.1016\/j.abb.2025.110294","DOI":"10.1016\/j.abb.2025.110294"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"Xia N. Li H. (2017). The role of perivascular adipose tissue in obesity-induced vascular dysfunction. British Journal of Pharmacology 174(20) 3425\u20133442. https:\/\/doi.org\/10.1111\/bph.13650","DOI":"10.1111\/bph.13650"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Yang G. R. Lv C. Lv K. K. Wu Y. Y. Hao X. W. Yuan Q. Song T. (2025). Age-related changes in the impact of metabolic syndrome on prostate volume: A cross-sectional study. Asian Journal of Andrology 27(4) 475\u2013481. https:\/\/doi.org\/10.4103\/aja2024101","DOI":"10.4103\/aja2024101"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Zhang X. Zeng X. Liu Y. Dong L. Zhao X. Qu X. (2014). Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urologia Internationalis 93(2) 214\u2013219. https:\/\/doi.org\/10.1159\/000357760","DOI":"10.1159\/000357760"}],"container-title":["American Journal of Men's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883261436335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15579883261436335","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883261436335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:28:39Z","timestamp":1777505319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15579883261436335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/15579883261436335"],"URL":"https:\/\/doi.org\/10.1177\/15579883261436335","relation":{},"ISSN":["1557-9883","1557-9891"],"issn-type":[{"value":"1557-9883","type":"print"},{"value":"1557-9891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"article-number":"15579883261436335"}}